Johnson and Johnson is to say goodbye to its group worldwide chair Sandra Peterson, as the second-in-command leader will retire from her post from 1 October.
Peterson has held the role for six years, during which time she oversaw the company’s global operating infrastructure, implemented innovation and growth initiatives and supervised the consumer-facing businesses, the latter generating around £18bn in revenue for the company.
She was also tasked with getting that particular division back on track after J&J was plagued by a series of recalls, including 200,000 bottles of children’s cough drop medicine that was deployed in the US.
Peterson has also led J&J’s efforts in healthcare technology, leveraging design thinking to create solutions for patients, consumers and providers.
J&J says that after her departure, her responsibilities will be shared between Joaquin Duato, who has been leading the company’s pharmaceutical business and chief scientific officer Paul Stoffels.
Additional changes will see Jennifer Taubert succeed Duato, taking the helm of J&J’s global pharmaceutical business while Ashley McEvoy – who rejuvenated its eye-care business – will manage J&J’s group of medical device companies.
Finally, Kathy Wengel, who oversees the company’s manufacturing and Michael Sneed, chief communication officer, has been promoted to join J&J’s executive team, these moves taking place from 2 July.